Menu
Back to Journals » Clinical Audit » Volume 4
Telavancin in the treatment of invasive Gram-positive infections
Authors Keynan Y, Rubinstein E
Received 5 March 2012
Accepted for publication 11 August 2012
Published 1 November 2012 Volume 2012:4 Pages 25—29
DOI https://doi.org/10.2147/CA.S30127
Review by Single anonymous peer review
Peer reviewer comments 2
Yoav Keynan,1–4 Ethan Rubinstein2,3
1Department of Community Health Sciences, 2Department of Medical Microbiology, 3Department of Internal Medicine, University of Manitoba, Winnipeg, Canada; 4Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya
Abstract: Telavancin is a newer once-daily lipoglycopeptide with activity against Gram-positive bacteria, including those that are resistant to conventional antibiotics like beta-lactams. The results of recent clinical trials led to registration of telavancin for use in skin and skin structure infections in the US and Canada and for nosocomial pneumonia in Europe, based primarily on the favorable results of clinical trials. We review the evidence for use of telavancin in Gram-positive intravascular infections, focusing on bacteremic subpopulations in the large clinical trials as well as anecdotal evidence for use of the drug in the setting of infective endocarditis.
Keywords: telavancin, Gram-positive bacteria, skin infections, infective endocarditis
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.